Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14005-14025

  Lamb, Rebecca ^a,b   Fiorillo, Marco ^a,b,c   Chadwick, Amy ^a,b   Ozsvari, Bela ^a,b   Reeves, Kimberly J ^a,b   Smith, Duncan L ^d   Clarke, Robert B ^a   Howell, Sacha J ^a   Cappello, Anna Rita ^c   Martinez Outschoorn, Ubaldo E ^e   Peiris Pagès, Maria ^a,b   Sotgia, Federica ^a,b   Lisanti, Michael P ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

DNA PK; Doxycycline; Mitochondrial biogenesis; Proteomic analysis; Radiation resistance

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; DOXYCYCLINE; ENZYME INHIBITOR; KU 57788; MITOCHONDRIAL DNA; NOTCH RECEPTOR; NU 7441; SONIC HEDGEHOG PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; RADIOSENSITIZING AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER STEM CELL; CANCER STEM LIKE CELL; CELL ACTIVITY; CELL EXPANSION; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; GLYCOLYSIS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; STEM CELL; T47D CELL LINE; TUMOR CELL; TUMOR INITIATING CELL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; PROTEOMICS; RADIATION RESPONSE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-ACTIVATED PROTEIN KINASE; DOWN-REGULATION; DOXYCYCLINE; FEMALE; HUMANS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; PROTEOMICS; RADIATION-SENSITIZING AGENTS;

EID: 84931045732     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4159     Document Type: Article

References (47)

1. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP, Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5:11029-11037.
2. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial agents and chemotherapy. 2006; 50:2042-2049.
3. Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, Mottis A, Jovaisaite V, Frochaux MV, Quiros PM, Deplancke B, Houtkooper RH, Auwerx J. Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. Cell reports. 2015.
4. Riesbeck K, Bredberg A, Forsgren A. Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrobial agents and chemotherapy. 1990; 34:167-169.
5. Bottger EC, Springer B, Prammananan T, Kidan Y, Sander P. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO reports. 2001; 2:318-323.
6. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Molecular cell. 2007; 26:393-402.
7. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015.
8. Kircik LH. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. Journal of drugs in dermatology: JDD. 2010; 9:1407-1411.
9. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991; 48:411-417.
10. Ahler E, Sullivan WJ, Cass A, Braas D, York AG, Bensinger SJ, Graeber TG, Christofk HR. Doxycycline alters metabolism and proliferation of human cell lines. PloS one. 2013; 8:e64561.
11. Zhang L, Ging NC, Komoda T, Hanada T, Suzuki T, Watanabe K. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS letters. 2005; 579:6423-6427.
12. Zimorski V, Ku C, Martin WF, Gould SB. Endosymbiotic theory for organelle origins. Current opinion in microbiology. 2014; 22:38-48.
13. Degli Esposti M, Chouaia B, Comandatore F, Crotti E, Sassera D, Lievens PM, Daffonchio D, Bandi C. Evolution of mitochondria reconstructed from the energy metabolism of living bacteria. PloS one. 2014; 9:e96566.
14. Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, Ponzoni M. A woman and her canary: a tale of chlamydiae and lymphomas. Journal of the National Cancer Institute. 2007; 99:1418-1419.
15. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. Journal of the National Cancer Institute. 2006; 98:1375-1382.
16. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther. 2007; 6:1684-90.
17. Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG, Singh G. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer research. 2002; 62:1588-1591.
18. Davis AJ, Lee KJ, Chen DJ. The N-terminal region of the DNA-dependent protein kinase catalytic subunit is required for its DNA double-stranded break-mediated activation. The Journal of biological chemistry. 2013; 288:7037-7046.
19. Davis AJ, Chen BP, Chen DJ. DNA-PK: a dynamic enzyme in a versatile DSB repair pathway. DNA repair. 2014; 17:21-29.
20. Papeta N, Zheng Z, Schon EA, Brosel S, Altintas MM, Nasr SH, Reiser J, D'Agati VD, Gharavi AG. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. The Journal of clinical investigation. 2010; 120:4055-4064.
21. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Weaver D, Muss H, Plaut K. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast cancer research and treatment. 2009; 114:47-62.
22. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith GC, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. Journal of medicinal chemistry. 2005; 48:7829-7846.
23. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer research. 2006; 66:5354-5362.
24. Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast cancer research and treatment. 2014; 143:47-55.
25. Hsu FM, Zhang S, Chen BP. Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Translational cancer research. 2012; 1:22-34.
26. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochemical pharmacology. 2008; 76:1352-1364.
27. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. The Journal of pathology. 2012; 226:380-393.
28. Kwon OJ, Valdez JM, Zhang L, Zhang B, Wei X, Su Q, Ittmann MM, Creighton CJ, Xin L. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nature communications. 2014; 5:4416.
29. Rix U and Superti-furga, G. Target profiling of small molecules by chemical proteomics. Nature chemical biology. 2009; 5:616-624.
30. Jeffery DA, Bogyo M. Chemical proteomics and its application to drug discovery. Current opinion in biotechnology. 2003; 14:87-95.
31. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene. 2007; 26:7816-7824.
32. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, Huang H, Burgess LE, Kesicki EA, Halbrook J. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Molecular cancer therapeutics. 2003; 2:1257-1264.
33. An J, Xu QZ, Sui JL, Bai B, Zhou PK. Downregulation of c-myc protein by siRNA-mediated silencing of DNA-PKcs in HeLa cells. International journal of cancer Journal international du cancer. 2005; 117:531-537.
34. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer research. 2002; 62:6400-6404.
35. Novotna E, Tichy A, Pejchal J, Lukasova E, Salovska B, Vavrova J. DNA-dependent protein kinase and its inhibition in support of radiotherapy. International journal of radiation biology. 2013; 89:416-423.
36. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. British journal of cancer. 2005; 93:1011-1018.
37. Davidson D, Amrein L, Panasci L, Aloyz R. Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Frontiers in pharmacology. 2013; 4:5.
38. Goodwin JF, Knudsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer discovery. 2014; 4:1126-1139.
39. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini reviews in medicinal chemistry. 2012; 12:44-52.
40. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrobial agents and chemotherapy. 1977; 11:462-469.
41. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, Howell SJ, Clarke RB. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:643-656.
42. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer research. 2010; 70:709-718.
43. Aukett RJ, Burns JE, Greener AG, Harrison RM, Moretti C, Nahum AE, Rosser KE, Party IW. Addendum to the IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential. 0.035 mm Al-4 mm Cu HVL. Physics in medicine and biology. 2005; 50:2739-2748.
44. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G, Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. Journal of mammary gland biology and neoplasia. 2012; 17:111-117.
45. Holland M, Castro FV, Alexander S, Smith D, Liu J, Walker M, Bitton D, Mulryan K, Ashton G, Blaylock M, Bagley S, Connolly Y, Bridgeman J, Miller C, Krishnan S, Dempsey C, et al. RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood. 2011; 118:638-649.
46. Peiris-Pagès M, Sotgia F, Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signaling in breast cancer cells. Oncotarget. 2015; In Press.
47. Fiorillo M, Verre AF, Iliut M, Peiris-Pagés M, Ozsvari B, Gandara R, Cappello AR, Sotgia F, Vijayaraghavan A, Lisanti MP. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for nontoxic cancer treatment, via "differentiation-based nanotherapy". Oncotarget. 2015; 6:3553-62.